Stivarga® Tablets for Colorectal Cancer

Stivarga® is an oral kinase inhibitor used to treat certain advanced cancers. It is commonly used after other treatments stop working. This page explains how the treatment works, who it may suit, and how to arrange US delivery from Canada. It also covers Stivarga cost without insurance so patients can plan ahead.

What Stivarga Is and How It Works

Border Free Health connects U.S. patients with licensed Canadian partner pharmacies; prescriptions are verified with prescribers before dispensing.

This medicine contains regorafenib, a multikinase inhibitor. It helps block signals that support tumor growth and blood vessel formation. The treatment is approved for metastatic colorectal cancer previously treated with standard therapies, unresectable or metastatic gastrointestinal stromal tumor after imatinib and sunitinib, and hepatocellular carcinoma previously treated with sorafenib. Details and limits of use are set in the official labeling.

By targeting multiple kinases, the therapy may slow disease progression in select patients. It is not a cure. Clinical decisions depend on tumor type, prior therapies, biomarkers, and overall health. Review the full prescribing information for complete guidance.

For broader education on conditions, see Colorectal Cancer, Gastrointestinal Stromal Tumor, and Liver Cancer pages, plus our Cancer category.

Who It’s For

This therapy is intended for adults with: metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy; anti-VEGF therapy; and, if RAS wild-type, anti-EGFR therapy; unresectable or metastatic GIST previously treated with imatinib and sunitinib; hepatocellular carcinoma previously treated with sorafenib.

It should not be used in individuals with known severe hypersensitivity to regorafenib or its components. Clinicians carefully assess liver function, bleeding risk, wound healing status, and recent procedures before starting.

Dosage and Usage

Follow the prescribing information and your clinician’s instructions. The usual schedule in labeling is daily dosing for 21 days, then 7 days off, in 28-day cycles. Take the tablets after a low-fat breakfast to improve consistency of exposure. Swallow whole with water. Do not crush or chew.

Therapy often starts at a labeled dose and may be adjusted for safety. Laboratory monitoring is routine, especially liver tests early in treatment. Blood pressure should be checked regularly. If adverse effects occur, a prescriber may interrupt or adjust therapy per the label.

A treatment calendar can help keep cycles on track. Keep an updated list of all medicines and share it at each visit. If unsure about timing or meals, consult the official label or ask a clinician to clarify.

Strengths and Forms

The product is supplied as film-coated oral tablets. Commonly published presentations include Regorafenib 40 mg tablets in bottles. Availability can vary by partner pharmacy and jurisdiction.

Packaging and pill appearance may differ by manufacturer and country of origin. Pharmacist counseling is useful when the bottle or imprint looks different from prior fills.

Missed Dose and Timing

If a scheduled dose is missed, take it the same day as soon as remembered. If it is the next day, skip the missed dose and resume the regular schedule. Do not take two doses at once. If vomiting occurs after a dose, do not take an extra tablet. Label guidance emphasizes returning to the planned dosing pattern.

Storage and Travel Basics

Store at room temperature in the original container, tightly closed, and protected from moisture. Keep out of reach of children and pets. Do not use past the expiration date on the package. Avoid storing in bathrooms with high humidity.

When traveling, carry the labeled pharmacy container in a carry-on bag. Pack only what is needed for the trip plus a small buffer in case of delays. Keep a copy of the prescription or a clinic note for security checks. If crossing borders, confirm local rules for personal importation well in advance.

For broader education, see our article on screening and care: Colorectal Cancer Overview.

Benefits

This treatment offers an oral option when other therapies have been tried. Tablet administration means no infusion visits. Cyclic dosing may allow planned rest periods to support tolerability. The multikinase mechanism can act on several pathways linked to tumor growth. Patients often appreciate a consistent routine that fits with daily life.

Any potential benefit must be weighed against safety considerations. Regular check-ins and labs help guide whether to continue, pause, or adjust treatment. Quality-of-life goals should be part of each discussion.

Side Effects and Safety

Common side effects include:

• Hand-foot skin reaction
• Fatigue or weakness
• Diarrhea
• Decreased appetite and weight loss
• High blood pressure
• Mouth irritation
• Rash or dryness
• Hoarseness or voice changes

Serious risks can include liver toxicity, severe bleeding, gastrointestinal perforation or fistula, infection, heart events, and poor wound healing. Call a clinician right away for yellowing skin or eyes, dark urine, severe stomach pain, black stools, coughing blood, chest pain, shortness of breath, or sudden neurological changes. When used with insulin or sulfonylureas, hypoglycemia risk should be considered in the broader care plan if relevant.

Drug Interactions and Cautions

Strong CYP3A4 inducers or inhibitors can affect regorafenib levels. Certain antibiotics, antifungals, antivirals, seizure medicines, and herbal products such as St. John’s wort may interact. Anticoagulants and antiplatelet agents can increase bleeding risk.

Tell the prescriber about all prescription medicines, over-the-counter items, vitamins, and supplements. Inform the care team about recent or planned surgeries, dental work, uncontrolled hypertension, liver disease, or history of bleeding. Alcohol can worsen liver stress and should be discussed with a clinician.

What to Expect Over Time

Clinicians generally reassess tolerance during the first cycle, then at regular intervals. Some effects, like hand-foot reaction or fatigue, may appear early and require supportive care. Blood pressure trends and liver tests guide ongoing use. Imaging is scheduled as indicated to evaluate disease control.

Clear goals and consistent monitoring help align expectations. Symptom diaries, photo logs for skin changes, and home blood pressure readings can aid conversations at visits. If the plan changes, the care team will outline next steps based on the label and individual factors.

Learn more about prevention and screening in our awareness feature: Colorectal Cancer Awareness Month.

Compare With Alternatives

For certain patients with previously treated hepatocellular carcinoma, sorafenib was often used earlier in the course. Another option for later consideration in some cases is Nexavar, based on label specifics.

For metastatic colorectal cancer with a BRAF V600E mutation, targeted therapy may be appropriate in some settings. One option used in combination with an EGFR inhibitor is Braftovi, according to its indications. Therapy selection depends on tumor biology, tolerability, and prior regimens. Discuss specifics with the oncology team and consult approved labeling for each medicine.

Pricing and Access

Our platform highlights Canadian pricing and transparent options. Many patients also look for a Stivarga coupon; availability can change over time. We provide current information so patients and caregivers can plan with their clinicians. Ships from Canada to US with tracked fulfilment after prescription verification.

Cash-pay considerations differ by pharmacy and jurisdiction. If a prescriber suggests a multi-cycle plan, coordinating refills can lower administrative hassle. For general savings tips, visit Promotions for current offers when available.

Availability and Substitutions

Supply may vary. If the requested presentation is unavailable, a prescriber may recommend a comparable alternative per local standards. Decisions are made by the care team using clinical judgment.

Some regions may have authorized generics. Stivarga generic regorafenib references the same active ingredient but may differ in packaging or excipients. Pharmacists can advise on product equivalence according to regulations.

Patient Suitability and Cost-Saving Tips

Good candidates often have received and tolerated prior standard therapies consistent with labeling. Those with significant liver impairment, uncontrolled blood pressure, recent major surgery, or active bleeding risk may require additional evaluation. The oncology team will determine whether the benefit-risk profile is acceptable.

Consider practical steps that can support access and adherence:

• Multi-month planning: align cycles to reduce pharmacy trips
• Refill reminders: set calendar alerts for cycle restarts
• Clinician coordination: schedule labs before the next cycle
• Insurance review: confirm coverage rules and documentation
• Financial planning: discuss Regorafenib price and assistance options if eligible

When ordering, use encrypted checkout and keep the prescription accessible for verification.

Questions to Ask Your Clinician

• Is this treatment appropriate based on my prior therapies and tumor profile?
• What monitoring will be needed during early cycles?
• Which side effects should prompt a call or visit right away?
• How should dosing be adjusted if significant toxicity occurs?
• Are there drug or supplement interactions I should avoid?
• What are the goals of therapy and how will we assess them?

Authoritative Sources

FDA Prescribing Information

Health Canada Drug Product Database

Manufacturer Information

Ready to proceed? Order Stivarga online with US shipping from Canada and prompt, express shipping; temperature-controlled handling when required. This information is not a substitute for professional medical advice. Always consult a clinician and the official label.